Death Receptor 6 as a Prognostic Marker in Low-grade Glioma.
Adult
Biomarkers, Tumor
/ genetics
Blotting, Western
Brain Neoplasms
/ genetics
Databases, Genetic
Female
Glioma
/ genetics
Humans
Isocitrate Dehydrogenase
/ genetics
Male
Middle Aged
Mutation
Neoplasm Grading
Progression-Free Survival
Receptors, Tumor Necrosis Factor
/ genetics
Reverse Transcriptase Polymerase Chain Reaction
Time Factors
Death receptor 6
glioma
low-grade glioma
prognosis
survival
tumor necrosis factor receptor 21
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
01
11
2021
revised:
30
11
2021
accepted:
07
12
2021
entrez:
27
2
2022
pubmed:
28
2
2022
medline:
8
3
2022
Statut:
ppublish
Résumé
Low-grade gliomas (LGG) are heterogenous tumours, causing variable survivals in patients. Identifying molecular markers for a more accurate prognosis is, therefore, important. Since death receptor 6 (DR6) is up-regulated in gliomas and shows an aberrant signalling network, we tested its suitability as a prognostic marker. DR6 was investigated in patient samples via PCR and western blot. Clinical data were analysed and compared to The Cancer Genome Atlas (TCGA) 'brain lower grade glioma' dataset. DR6 was found to be enhanced in LGG and its expression increased in recurrent LGG. The receptor showed a protective effect in primary LGG with a significantly elongated progression-free survival that was confirmed in the TCGA study. This effect was reversed in relapsed LGG in which cases with high DR6 expression reveal a shorter overall survival. DR6 is an interesting candidate for further studies regarding its effect as a prognostic marker, playing an opposing role in primary and relapsed LGG.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
Low-grade gliomas (LGG) are heterogenous tumours, causing variable survivals in patients. Identifying molecular markers for a more accurate prognosis is, therefore, important. Since death receptor 6 (DR6) is up-regulated in gliomas and shows an aberrant signalling network, we tested its suitability as a prognostic marker.
MATERIALS AND METHODS
METHODS
DR6 was investigated in patient samples via PCR and western blot. Clinical data were analysed and compared to The Cancer Genome Atlas (TCGA) 'brain lower grade glioma' dataset.
RESULTS
RESULTS
DR6 was found to be enhanced in LGG and its expression increased in recurrent LGG. The receptor showed a protective effect in primary LGG with a significantly elongated progression-free survival that was confirmed in the TCGA study. This effect was reversed in relapsed LGG in which cases with high DR6 expression reveal a shorter overall survival.
CONCLUSION
CONCLUSIONS
DR6 is an interesting candidate for further studies regarding its effect as a prognostic marker, playing an opposing role in primary and relapsed LGG.
Identifiants
pubmed: 35220214
pii: 42/3/1237
doi: 10.21873/anticanres.15591
doi:
Substances chimiques
Biomarkers, Tumor
0
Receptors, Tumor Necrosis Factor
0
TNFRSF21 protein, human
0
Isocitrate Dehydrogenase
EC 1.1.1.41
IDH1 protein, human
EC 1.1.1.42.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1237-1245Informations de copyright
Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.